ClinicalTrials.gg
RecruitingNCT07295275Updated Mar 3, 2026

Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection

An observational study in Liver Cancer, sponsored by West China Hospital. Recruiting at 3 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by West China Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
200
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Liver Neoplasms by West China Hospital — 8 open to participants now, 8 under way, none of them phase 3. Liver Neoplasms · West China Hospital.

Started
2026
with 3 others
Observational
3 of 10
3 open now
Registered
7th of 10
by date

Among the 10 studies in Liver Neoplasms by West China Hospital, this one is one of 4 that started in 2026, is one of 3 observational ones, and was the 7th registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

8 of the 10 studies in Liver Neoplasms by West China Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Liver Neoplasms by West China Hospital, or all of them as a file.
02

Study summary

This multicenter, ambispective cohort study evaluates the safety and efficacy of trans-arterial Indocyanine Green (ICG) fluorescence-guided laparoscopic liver watershed resection for Hepatocellular Carcinoma (HCC). The study aims to compare the outcomes of the trans-arterial ICG staining approach versus the conventional trans-portal (portal vein) ICG staining approach.

Read the detailed description

The study employs an ambispective design, comprising:

A Retrospective Cohort: Collecting clinical data from patients treated between June 2020 and August 2025.

A Prospective Cohort: Enrolling new patients from January 2026 to January 2027. Data will be collected from three medical centers. The primary objective is to compare the oncological prognosis, specifically Recurrence-Free Survival (RFS), between the two navigation methods. Secondary objectives include perioperative safety, liver function recovery, and Overall Survival (OS).

03

Conditions studied

  • Liver Cancer

Keywords

  • Laparoscopic Anatomical Liver Resection
  • Indocyanine Green Fluorescence
  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 18 to 80 years with a histopathological diagnosis of Hepatocellular Carcinoma (HCC). The population consists of patients who have undergone (retrospective cohort) or are scheduled to undergo (prospective cohort) laparoscopic anatomical liver resection guided by Indocyanine Green (ICG) fluorescence imaging at one of the participating centers. Participants must have Child-Pugh class A or B liver function and no evidence of major vascular invasion or distant metastasis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years.
  2. Postoperative histopathological diagnosis of Hepatocellular Carcinoma (HCC).
  3. Underwent ICG fluorescence-guided laparoscopic anatomical liver resection.
  4. Class A or B.
  5. I-III.
  6. Performance Status 0-2.
  7. No invasion of major vessels (main portal vein/first-order branches, main hepatic vein).
  8. No distant .

Exclusion criteria

Exclusion Criteria:

  1. Pathology confirms non-HCC components (e.g., cholangiocarcinoma, combined HCC-ICC) or liver cancer.
  2. Concomitant other active .
  3. Preoperative anti-tumor therapy (TACE, ablation, radiotherapy, systemic therapy) or history of prior hepatectomy.
  4. Ruptured tumor.
  5. Conversion to open surgery.
  6. Unclear surgical records regarding ICG staining method.
  7. Intraoperative ICG staining failure (e.g., diffuse staining, unclear boundaries) preventing fluorescence-guided resection.
  8. Missing data preventing primary endpoint assessment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Transarterial ICG Group

    Patients who underwent laparoscopic anatomical liver resection guided by superselective transarterial injection of ICG.

    Procedure: Laparoscopic Anatomical Liver Resection (guided by transarterial injection of ICG)

  • Transportal ICG Group

    Patients who underwent laparoscopic anatomical liver resection guided by transportal (portal vein) injection of ICG.

Interventions

  • ProcedureLaparoscopic Anatomical Liver Resection (guided by transarterial injection of ICG)

    Laparoscopic liver resection using ICG fluorescence imaging for tumor and liver segment visualization. Comparison lies in the route of ICG administration (Arterial vs. Portal).

06

What researchers measure

Primary outcomes

  1. Recurrence-Free Survival (RFS)

    RFS is defined as the time interval from the date of surgery to the date of first documented tumor recurrence (intrahepatic or extrahepatic) or death from any cause. Evaluated using Kaplan-Meier analysis.

    Time frame: Up to 18 months post-surgery (assessing the 18-month RFS rate as a key benchmark)

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from the date of surgery to the date of death from any cause.

    Time frame: Up to 3 years post-surgery

  2. Incidence of Perioperative Complications

    Number of participants with postoperative complications (e.g., bile leakage, hemorrhage, infection, liver failure), graded according to the Clavien-Dindo classification system.

    Time frame: From surgery up to 90 days post-surgery

Other outcomes

  1. Liver Function Recovery

    Assessment of dynamic changes in liver function indicators, including Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Total Bilirubin (TBIL) levels.

    Time frame: Pre-operative, Post-operative Days 1, 3, 5, and 1 month

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Jan 2028, 22 months later.

Of 132 non-industry observational studies under Liver Neoplasms, half reached primary completion within 114 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 172. This study's planned 22 months is below that.

Counting every sponsor, half of 160 studies reached it within 59 months; a quarter within 34 and three quarters within 172.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2025
First posted
Dec 19, 2025
StartEst.
Mar 1, 2026
Primary completionEst.
Jan 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07295275
Responsible party
Jiwei Huang (Clinical Professor, West China Hospital) — Principal investigator
First posted
Dec 19, 2025
Start date
Mar 1, 2026 (estimated)
Primary completion
Jan 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Mar 3, 2026

Study contacts

Jiwei Huang Professor
Contact
huangjiwei@wchscu.cn
18980606725

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion